Shares of EKF Diagnostics Holdings plc (LON:EKF - Get Free Report) were up 27.3% during mid-day trading on Thursday . The company traded as high as GBX 26.90 ($0.36) and last traded at GBX 25.20 ($0.33). Approximately 2,253,335 shares changed hands during trading, an increase of 353% from the average daily volume of 497,132 shares. The stock had previously closed at GBX 19.80 ($0.26).
EKF Diagnostics Price Performance
The stock's 50-day moving average price is GBX 21.33 and its 200-day moving average price is GBX 23.89. The company has a market capitalization of £114.67 million, a price-to-earnings ratio of 24.01 and a beta of 0.57. The company has a quick ratio of 1.77, a current ratio of 4.60 and a debt-to-equity ratio of 0.34.
EKF Diagnostics (LON:EKF - Get Free Report) last announced its earnings results on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) earnings per share (EPS) for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. Equities research analysts anticipate that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current year.
Insider Transactions at EKF Diagnostics
In other EKF Diagnostics news, insider Gavin T. Jones purchased 50,000 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was acquired at an average cost of GBX 22 ($0.29) per share, with a total value of £11,000 ($14,612.11). 5.24% of the stock is owned by company insiders.
About EKF Diagnostics
(
Get Free Report)
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Featured Stories
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
